In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Efficacy and safety of non-vitamin K oral anticoagulants in hypertrophic cardiomyopathy with non-valvular atrial fibrillation: a nationwide cohort study

Session Atrial fibrillation in hypertrophic cardiomyopathy

Speaker Assistant Professor Pil-Sung Yang

Congress : ESC Congress 2018

  • Topic : arrhythmias and device therapy
  • Sub-topic : Hypertrophic Cardiomyopathy
  • Session type : Abstract Session
  • FP Number : 1468

Authors : H Jung (Seoul,KR), PS Yang (Seongnam,KR), E Jang (Seoul,KR), HT Yu (Seoul,KR), TH Kim (Seoul,KR), JS Uhm (Seoul,KR), JY Kim (Seoul,KR), JH Sung (Seongnam,KR), HN Pak (Seoul,KR), MH Lee (Seoul,KR), B Joung (Seoul,KR), GYH Lip (Birmingham,GB)

H. Jung1 , P.S. Yang2 , E. Jang1 , H.T. Yu1 , T.H. Kim1 , J.S. Uhm1 , J.Y. Kim1 , J.H. Sung2 , H.N. Pak1 , M.H. Lee1 , B. Joung1 , G.Y.H. Lip3 , 1Yonsei University Health System, cardiology - Seoul - Korea Republic of , 2Bundang CHA Medical Center, CHA University - Seongnam - Korea Republic of , 3University of Birmingham, Institute of Cardiovascular Sciences - Birmingham - United Kingdom ,

European Heart Journal ( 2018 ) 39 ( Supplement ), 274-275

Background: Chronic anticoagulation with warfarin is recommended in patients with hypertrophic cardiomyopathy (HCM) and atrial fibrillation (AF). Non-vitamin K oral anticoagulants (NOACs) are an alternative to warfarin but there are limited data to support their use in HCM.

Purpose: We sought to describe the pattern of use, stroke events, bleeding and mortality in patients with HCM and AF treated with NOACs, in comparison to those treated with warfarin.

Methods: Using the Korean National Health Insurance Service (NHIS) data during the period from 2011 to 2016, we identified patients with HCM and AF treated with NOACs (n=2302) and warfarin (n=1188). Comparisons on efficacy and safety outcomes were made on the basis of Cox-proportional hazards models stratified on 1:1 propensity score (PS)-matched NOAC (n=946) and warfarin groups (n=946).

Results: Baseline characteristics were well balanced between the two matched groups. Median age was 67 years (interquartile range: 58 to 74 years), 55.9% male, and median CHA2DS2-VASc score was 5 (interquartile range: 3 to 6). A total of 51.9% of the NOAC-treated patients received a reduced dose of dabigatran, rivaroxaban, or apixaban. After a mean 1.30 years of follow-up, the incidence of ischemic stroke and major bleeding were similar between NOAC- and warfarin treated patients. The incidence for ischemic stroke was 10.99 and 9.38 per 100 person-years for NOACs and warfarin, respectively (adjusted hazard ratio [aHR]: 0.996; 95% confidence interval [CI] 0.763–1.299; p=0.975). Major bleeding occurred in 5.48 per 100 person-years in the NOAC group vs. 5.26 in warfarin group (aHR: 0.932; 95% CI 0.649–1.338; p=0.703). However, patients treated with NOAC showed a significantly lower risk of all-cause mortality and the composite net clinical outcome (ischemic stroke, major bleeding, and all-cause death) compared to those on warfarin. The incidence of all-cause death was 4.98 and 10.69 per 100 person-years for NOACs and warfarin, respectively (aHR: 0.442; 95% CI 0.318–0.613; p<0.0001). The benefits were consistent across various high-risk subgroups.

Conclusions: Compared with those with warfarin, HCM patients with AF on NOACs had lower risk of all-cause mortality and similar risk of major bleeding and ischemic stroke.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are